Cargando…

Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine

BACKGROUND: Effective vaccines against coronavirus disease 2019 (COVID-19) are available worldwide; however, the longevity of vaccine effectiveness is not known. OBJECTIVE: We performed a prospective observational study to assess the antibody response of healthcare workers against severe acute respi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Jae Hong, Kim, Young Ree, Heo, Sang Taek, Oh, Hyunjoo, Kim, Misun, Lee, Hyang Ran, Yoo, Jeong Rae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842222/ https://www.ncbi.nlm.nih.gov/pubmed/35173736 http://dx.doi.org/10.3389/fimmu.2022.827306

Ejemplares similares

Antimicrobial Susceptibility Trends of Streptococcus pneumoniae by Age Groups Over Recent 10 Years in a Single Hospital in South Korea
por: Oh, Hyunjoo, et al.
Publicado: (2021)

Clinical Characteristics and Risk Factors for Severe Disease of Coronavirus Disease 2019 in a Low Case Fatality Rate Region in Korea
por: Kim, Misun, et al.
Publicado: (2021)

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
por: Lee, Yun Woo, et al.
Publicado: (2021)

Aseptic Meningitis Following Second Dose of an mRNA Coronavirus Disease 2019 Vaccine in a Healthy Male: Case Report and Literature Review
por: Kang, Han Sol, et al.
Publicado: (2022)

Prognostic Factors of Severe Fever with Thrombocytopenia Syndrome in South Korea
por: Kim, Misun, et al.
Publicado: (2020)

The first case of abdominal mycotic aneurysm caused by K1 hypervirulent Klebsiella pneumoniae in a healthy adult
por: Kim, Misun, et al.
Publicado: (2021)

Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study
por: Kim, Hyun Jin, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib
por: Ikeda, Daisuke, et al.
Publicado: (2022)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

DIAPHRAGMATIC PARALYSIS FOLLOWING SECOND DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE
por: PRUDENTI, JOHN A, et al.
Publicado: (2022)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Delayed Diagnosis of Tuberculosis Mistaken for Tinea Corporis in a Healthy Adult
por: Kim, Jae-Wang, et al.
Publicado: (2021)

Epidemiologic and Clinical Characteristics of Patients with Severe Fever with Thrombocytopenia Syndrome at Tertiary Hospital in Jeju for 10 years
por: Kim, Jae Yeon, et al.
Publicado: (2023)

Devastating Community-Acquired Bacterial Meningitis Caused by Hypervirulent Klebsiella pneumoniae in an Immunocompetent Patient
por: Oh, Hyunjoo, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination
por: Ishii, Takashi, et al.
Publicado: (2023)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
por: Gandolfo, Claudia, et al.
Publicado: (2022)

The SARS-CoV-2–neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine
por: Pedersen, Rune M., et al.
Publicado: (2021)

Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
por: Markewitz, Robert, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Phylogenetic Analysis for the Origin of Typhoid Fever Outbreak on Jeju Island, Korea, in 2017
por: Lee, Keun Hwa, et al.
Publicado: (2020)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

1776. Coinfection of severe fever with thrombocytopenia syndrome virus and Coxiella burnetii infection by the developmental stage of hard ticks in the subtropical region of South Korea
por: Kim, Yuyeon, et al.
Publicado: (2023)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
por: Li, Tingting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ab8qq1qtcev7u49tkuiq8ckr5f